NUVL - Nuvalent Inc - Ordinary Shares - Class A
IEX Last Trade
85.13
-0.370 -0.435%
Share volume: 246,103
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$85.50
-0.37
-0.43%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-0.22%
1 Month
9.28%
3 Months
28.05%
6 Months
-0.27%
1 Year
84.86%
2 Year
437.44%
Key data
Stock price
$85.13
DAY RANGE
N/A - N/A
52 WEEK RANGE
$39.86 - $89.39
52 WEEK CHANGE
$0.83
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO:
Region: US
Website:
Employees: 74
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 74
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
nuvalent is improving human health by developing breakthrough small molecule therapeutics that engage biological targets in new ways using cutting-edge chemical insights. by expanding the universe of targets that interact with small molecules, we are generating therapeutics with activities not previously possible, including modulation of ‘undruggable’ targets. our unique approach is leading to first-in-class and best-in-class small molecule therapeutics that will significantly impact patient’s lives.
Recent news